Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 10/20 | 0.54 |
| ▸ | MELK | Q14680 | 1/20 | 0.43 |
| ▸ | PARP2 | Q9UGN5 | 5/20 | 0.43 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.43 |
| ▸ | AXL | P30530 | 1/20 | 0.42 |
| ▸ | MERTK | Q12866 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3955549 | 0.77 | PARP1 (0.52) | PARP1PARP2 | |
| SCHEMBL28309739 | 0.75 | LMNA (0.56) | PARP1PARP2PARP3CHEK1 | |
| SCHEMBL18616276 | 0.75 | AXL (0.58) | PARP1MELKPARP2PARP3AXL | |
| SCHEMBL28684963 | 0.72 | PARP1 (0.58) | PARP1PARP2PARP3AXLMERTK | |
| SCHEMBL30108265 | 0.72 | PARP1 (0.58) | PARP1PARP2PARP3AXLMERTK | |
| SCHEMBL16042922 | 0.70 | PARP1 (0.59) | PARP1PARP2PARP3CHRM3CHEK1 | |
| SCHEMBL27639656 | 0.70 | KDR (0.53) | PARP1MELKPARP2PARP3CHEK1 | |
| SCHEMBL31582419 | 0.69 | PARP1 (0.42) | PARP1PARP2 | |
| SCHEMBL6072051 | 0.68 | HDAC6 (0.57) | PARP1CHRM3 | |
| SCHEMBL12725365 | 0.68 | PRMT6 (0.61) | PARP1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12378224-B2 | Heteroaryl compounds and their use as Mer inhibitors | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2025-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12378224-B2 | Heteroaryl compounds and their use as Mer inhibitors | MERTK, RET, ERBB2 | PARP1 4481/4885MELK 207/4885PARP2 4673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.